Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Autoimmune Disorders

  Free Subscription

Articles published in Kidney Int

Retrieve available abstracts of 81 articles:
HTML format

Single Articles

    December 2022
  1. CHEN A, Lee K, He JC
    Treating crescentic glomerulonephritis by targeting macrophages.
    Kidney Int. 2022;102:1212-1214.
    PubMed     Abstract available

    November 2022
    Endothelium and endothelin: regulators of arterial stiffness and fibrinolysis in ANCA-associated vasculitis.
    Kidney Int. 2022;102:963-966.
    PubMed     Abstract available

  3. FARRAH TE, Melville V, Czopek A, Fok H, et al
    Arterial stiffness, endothelial dysfunction and impaired fibrinolysis are pathogenic mechanisms contributing to cardiovascular risk in ANCA-associated vasculitis.
    Kidney Int. 2022;102:1115-1126.
    PubMed     Abstract available

  4. SHIM JS, Kim EJ, Lee LE, Kim JY, et al
    The oxidative phosphorylation inhibitor IM156 suppresses B-cell activation by regulating mitochondrial membrane potential and contributes to the mitigation of systemic lupus erythematosus.
    Kidney Int. 2022 Nov 1. pii: S0085-2538(22)00913.
    PubMed     Abstract available

    October 2022
  5. HOXHA E, Reinhard L, Castedello T, Becker JU, et al
    False positivity for PLA2R1-antibody measured by ELISA in a nephrotic patient with no membranous nephropathy.
    Kidney Int. 2022 Oct 5. pii: S0085-2538(22)00807.

  6. JACKSON SW, Alpers CE
    Lupus nephritis transcriptomics across space and time.
    Kidney Int. 2022;102:694-696.
    PubMed     Abstract available

    September 2022
  7. TOMAS NM, Dehde S, Meyer-Schwesinger C, Huang M, et al
    Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice.
    Kidney Int. 2022 Sep 30. pii: S0085-2538(22)00804.
    PubMed     Abstract available

  8. DIEBOLD M, Locher E, Boide P, Enzler-Tschudy A, et al
    Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased.
    Kidney Int. 2022 Sep 9. pii: S0085-2538(22)00697.
    PubMed     Abstract available

  9. KURIEN AA, Jansi Prema KS, Walker P, Caza T, et al
    Traditional indigenous medicines are an etiologic consideration for NELL1-positive membranous nephropathy.
    Kidney Int. 2022 Sep 9. pii: S0085-2538(22)00712.

  10. LUO C, Ouyang Y, Shi S, Li G, et al
    Particulate matter of air pollution may increase risk of kidney failure in IgA nephropathy.
    Kidney Int. 2022 Sep 7. pii: S0085-2538(22)00696.
    PubMed     Abstract available

    August 2022
  11. TODA E, Sawada A, Takeuchi K, Wakamatsu K, et al
    Inhibition of the chemokine signal regulator FROUNT by disulfiram ameliorates crescentic glomerulonephritis.
    Kidney Int. 2022 Aug 29. pii: S0085-2538(22)00687.
    PubMed     Abstract available

  12. CHANG JC, Weiss PF, Xiao R, Atkinson MA, et al
    Use of renin angiotensin aldosterone system inhibitors in children with lupus and time to glucocorticoid discontinuation.
    Kidney Int. 2022;102:395-404.
    PubMed     Abstract available

  13. YU XJ, Wang SX
    Recognizing the true face of noninfectious cryoglobulinemic glomerulonephritis.
    Kidney Int. 2022;102:238-241.
    PubMed     Abstract available

    July 2022
  14. FLOEGE J, Wied S, Rauen T
    Assessing prognosis in IgA nephropathy.
    Kidney Int. 2022;102:22-24.
    PubMed     Abstract available

  15. PARIKH SV, Malvar A, Song H, Shapiro J, et al
    Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis.
    Kidney Int. 2022 Jul 1. pii: S0085-2538(22)00512.
    PubMed     Abstract available

    June 2022
  16. MISRA DP, Agarwal V
    Management of refractory lupus nephritis: rationale to consider tacrolimus.
    Kidney Int. 2022;101:1293.

  17. LODI L, Mastrolia MV, Bello F, Rossi GM, et al
    Type I interferon-related kidney disorders.
    Kidney Int. 2022;101:1142-1159.
    PubMed     Abstract available

    May 2022
  18. MONTAGUD-MARRAHI E, Cuadrado-Payan E, Hermida E, Cacho J, et al
    Preemptive simultaneous pancreas kidney transplantation has survival benefit to patient.
    Kidney Int. 2022 May 26. pii: S0085-2538(22)00385.
    PubMed     Abstract available

  19. JAVAUGUE V, Valeri AM, Sathick IJ, Said SM, et al
    The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis.
    Kidney Int. 2022 May 2. pii: S0085-2538(22)00349.
    PubMed     Abstract available

    April 2022
  20. BARBOUR SJ, Coppo R, Zhang H, Liu ZH, et al
    Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy.
    Kidney Int. 2022 Apr 29. pii: S0085-2538(22)00342.
    PubMed     Abstract available

    March 2022
  21. VINK CH, van Cranenbroek B, van der Heijden JW, Koenen HPJM, et al
    Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy.
    Kidney Int. 2022;101:646-647.

  22. CHENG L, Gou SJ
    Whether the addition of high-dosage methylprednisolone to plasma exchange was more effective than plasma exchange in the treatment for severe antineutrophil cytoplasmic antibody-associated vasculitis?
    Kidney Int. 2022;101:647-648.

    February 2022
  23. KANT S, Azar A, Geetha D
    Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2022;101:414-415.

  24. CAZA TN, Larsen CP
    Lipoic acid in neural epidermal growth factor-like 1-associated membranous nephropathy: more than a coincidence?
    Kidney Int. 2022;101:418-419.

  25. STEHLE T, Grimbert P, Remy P, Moktefi A, et al
    Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression.
    Kidney Int. 2022;101:416-418.

  26. GLEESON S, Lightstone L
    BLISS-LN trial revisited: function matters.
    Kidney Int. 2022;101:224-226.
    PubMed     Abstract available

  27. DHAUN N, McAdoo SP
    The changing role of glucocorticoids in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2022;101:201-204.

    January 2022
  28. KIM HJ, Jung M, Lim BJ, Han SH, et al
    New Onset of Class III Lupus Nephritis with Multi-Organ Involvement after COVID -19 Vaccination.
    Kidney Int. 2022 Jan 30. pii: S0085-2538(22)00064.

  29. LI X, Zhang X
    Comments on the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for anticoagulant therapy in patients with membranous nephropathy.
    Kidney Int. 2022;101:186-187.

  30. KLOMJIT N, Zand L
    Catastrophic kidney infarction.
    Kidney Int. 2022;101:189.

    December 2021
  31. ZAMBRANO S, He L, Kano T, Sun Y, et al
    Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing.
    Kidney Int. 2021 Dec 27. pii: S0085-2538(21)01211.
    PubMed     Abstract available

  32. AYOUB I, Wolf BJ, Geng L, Song H, et al
    Prediction Models of Treatment Response in Lupus Nephritis.
    Kidney Int. 2021 Dec 3. pii: S0085-2538(21)01079.
    PubMed     Abstract available

  33. PLAISIER E, Not A, Buob D, Ronco P, et al
    Contactin-1-associated membranous nephropathy: complete immunologic and clinical remission with rituximab.
    Kidney Int. 2021;100:1342-1344.

  34. MULLER R, Lebrun G
    Strawberry gingivitis.
    Kidney Int. 2021;100:1353.

  35. ENGHARD P, Zickler D, Sonnemann J, Schneider W, et al
    Imlifidase as novel treatment strategy in anti-neutrophil cytoplasmic antibody-induced pulmonary-renal syndrome.
    Kidney Int. 2021;100:1344-1345.

  36. DEBIEC H, Ronco P
    When contactin antibodies hit the podocyte: a new neurorenal syndrome.
    Kidney Int. 2021;100:1163-1165.
    PubMed     Abstract available

  37. GULATI K, Edwards H, Prendecki M, Cairns TD, et al
    Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2021;100:1316-1324.
    PubMed     Abstract available

    How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not.
    Kidney Int. 2021;100:1185-1189.
    PubMed     Abstract available

    November 2021
  39. KANT S, Geetha D
    Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti-neutrophil cytoplasmic antibody vasculitis.
    Kidney Int. 2021;100:1124-1127.

  40. HENDRA H, Mahalingasivam V, Salama AD, Burns A, et al
    The Case | Unexplained inflammation after treatment for granulomatosis with polyangiitis.
    Kidney Int. 2021;100:1147-1148.

    October 2021
  41. CAMBIER A, Gleeson PJ, Abbad L, Canesi F, et al
    Kidney Int. 2021 Oct 28. pii: S0085-2538(21)00954.
    PubMed     Abstract available

  42. SPAIN RI, Andeen NK, Gibson PC, Samuels M, et al
    Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy.
    Kidney Int. 2021 Oct 16. pii: S0085-2538(21)00946.
    PubMed     Abstract available

  43. MEJIA-VILET JM, Malvar A, Arazi A, Rovin BH, et al
    The Lupus Nephritis Management Renaissance.
    Kidney Int. 2021 Oct 4. pii: S0085-2538(21)00874.
    PubMed     Abstract available

  44. VILLA M, Diaz-Crespo F, Perez de Jose A, Verdalles U, et al
    A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
    Kidney Int. 2021;100:937-938.

  45. LE QUINTREC M, Teisseyre M, Bec N, Delmont E, et al
    Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy.
    Kidney Int. 2021 Oct 1. pii: S0085-2538(21)00806.
    PubMed     Abstract available

  46. ROVIN BH, Adler SG, Barratt J, Bridoux F, et al
    Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
    Kidney Int. 2021;100:753-779.
    PubMed     Abstract available

  47. ROCCATELLO D, Sciascia S
    A toggle switch linking coagulation and innate immunity in antiphospholipid antibody syndrome.
    Kidney Int. 2021;100:740-742.

    September 2021
  48. ZAVALA-MIRANDA MF, Gonzalez-Ibarra SG, Perez-Arias AA, Uribe-Uribe NO, et al
    New onset systemic lupus erythematosus opening as class V lupus nephritis after COVID-19 vaccination.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00869.

  49. ROVIN BH, Furie R, Teng YKO, Contreras G, et al
    A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00862.
    PubMed     Abstract available

  50. HUERTA A, Caballero Bermejo AF, de Villa LF, Sedano R, et al
    Measurement of the passage of mycophenolic acid into breast milk in a patient with lupus nephritis.
    Kidney Int. 2021;100:711.

  51. SALHI S, Ribes D, Colombat M, Fortenfant F, et al
    Bortezomib plus dexamethasone for rituximab-resistant PLA2R(+) membranous nephropathy.
    Kidney Int. 2021;100:708-709.

  52. BORZA DB
    Fumarate in membranous nephropathy: more questions than answers.
    Kidney Int. 2021;100:707.

    August 2021
  53. GUEGUEN L, Loheac C, Saidani N, Khatchatourian L, et al
    Membranous nephropathy following anti-Covid-19 mRNA vaccination.
    Kidney Int. 2021 Aug 19. pii: S0085-2538(21)00757.

  54. TUSCHEN K, Brasen JH, Schmitz J, Vischedyk M, et al
    Relapse of Class V Lupus Nephritis after Vaccination with COVID-19 mRNA Vaccine.
    Kidney Int. 2021 Aug 2. pii: S0085-2538(21)00738.

  55. PLASSE R, Nee R, Gao S, Olson S, et al
    AKI with Gross Hematuria and IgA Nephropathy after COVID Vaccine.
    Kidney Int. 2021 Aug 2. pii: S0085-2538(21)00739.

    July 2021
  56. DA Y, Goh GH, Khatri P
    A Case of Membranous Nephropathy Following Pfizer-BioNTech mRNA vaccine against Coronavirus 2019.
    Kidney Int. 2021 Jul 29. pii: S0085-2538(21)00735.

  57. HANNA C, Herrera Hernandez LP, Bu L, Kizilbash S, et al
    IgA Nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine.
    Kidney Int. 2021 Jul 5. pii: S0085-2538(21)00666.

  58. RABANT M, Dessaix K, Buob D, Fagniez O, et al
    The Case | Membranous nephropathy after alemtuzumab treatment.
    Kidney Int. 2021;100:249-250.

  59. BERCHTOLD L, Letouze E, Alexander MP, Canaud G, et al
    Corrigendum to Berchtold L, Letouze E, Alexander MP, et al. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney Int. 2021;99:671-685.
    Kidney Int. 2021;100:243.

    June 2021
  60. KUDOSE S, Friedman P, Albajrami O, D'Agati VD, et al
    Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy.
    Kidney Int. 2021 Jun 17. pii: S0085-2538(21)00598.

  61. PERRIN P, Bassand X, Benotmane I, Bouvier N, et al
    Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy.
    Kidney Int. 2021 Jun 1. pii: S0085-2538(21)00564.

  62. NANGAKU M, Fogo AB
    Does a preclinical randomized controlled trial, pRCT, resolve the gap between animal studies and human trials?
    Kidney Int. 2021;99:1262-1264.
    PubMed     Abstract available

    May 2021
  63. SEKAR A, Campbell R, Tabbara J, Rastogi P, et al
    ANCA glomerulonephritis post Moderna COVID-19 vaccination.
    Kidney Int. 2021 May 31. pii: S0085-2538(21)00555.

  64. TAN HZ, Tan RY, Jun Choo JC, Lim CC, et al
    Is COVID-19 Vaccination unmasking Glomerulonephritis?
    Kidney Int. 2021 May 22. pii: S0085-2538(21)00504.

  65. AYDIN MF, Yildiz A, Oruc A, Sezen M, et al
    Relapse of Primary Membranous Nephropathy after inactivated SARS-CoV-2 Virus Vaccination.
    Kidney Int. 2021 May 13. pii: S0085-2538(21)00494.

  66. KANO T, Suzuki H, Makita Y, Fukao Y, et al
    Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy.
    Kidney Int. 2021 May 4. pii: S0085-2538(21)00467.
    PubMed     Abstract available

  67. CHAPMAN FA, Dhaun N
    STARMEN: progress in membranous nephropathy?
    Kidney Int. 2021;99:1242-1243.

    An impending obituary for the primacy of P values in glomerulonephritis trial results?
    Kidney Int. 2021;99:1241-1242.

  69. FERNANDEZ-JUAREZ G, Rojas-Rivera J, Praga M
    The authors reply.
    Kidney Int. 2021;99:1243.

  70. ANDERS HJ, Lei Y, Rovin BH
    The authors reply.
    Kidney Int. 2021;99:1242.

    April 2021
  71. GUL RAHIM SE, Lin J, Wang JC
    A case of gross hematuria and IgA Nephropathy Flare up following SARS-CoV-2 vaccination.
    Kidney Int. 2021 Apr 28. pii: S0085-2538(21)00465.

  72. WHEELER DC, Toto RD, Stefansson BV, Jongs N, et al
    A pre-specified analysis of the DAPA-CKD trial indicates effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
    Kidney Int. 2021 Apr 17. pii: S0085-2538(21)00396.
    PubMed     Abstract available

  73. BARRATT J, Floege J
    SGLT-2 inhibition in IgA nephropathy: the new standard-of-care?
    Kidney Int. 2021 Apr 17. pii: S0085-2538(21)00385.
    PubMed     Abstract available

  74. LERNER GB, Virmani S, Henderson JM, Francis JM, et al
    A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy.
    Kidney Int. 2021 Apr 12. pii: S0085-2538(21)00377.
    PubMed     Abstract available

  75. SANTORIELLO D, Bomback AS, Kudose S, Batal I, et al
    Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine.
    Kidney Int. 2021 Apr 12. pii: S0085-2538(21)00379.
    PubMed     Abstract available

    March 2021
  76. FARRAH TE, Dhaun N
    Antineutrophil cytoplasm antibody positivity, kidney impairment, and cholesterol embolization.
    Kidney Int. 2021;99:774.

    January 2021
  77. RONCO P, Rovin B, Nangaku M, Wyatt C, et al
    Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology.
    Kidney Int. 2021;99:2-4.

  78. KUDOSE S, Santoriello D, Debiec H, Canetta PA, et al
    The clinicopathologic spectrum of segmental membranous glomerulopathy.
    Kidney Int. 2021;99:247-255.
    PubMed     Abstract available

    November 2020
  79. TURNER MP, Storey BC, Mittal S, Macanovic J, et al
    Candida crescents in a renal allograft.
    Kidney Int. 2020;98:1356.

    September 2020
  80. SCHENA FP, Anelli VW, Trotta J, Di Noia T, et al
    Development and testing of an artificial intelligence tool for predicting end stage kidney disease in patients with immunoglobulin A nephropathy.
    Kidney Int. 2020 Sep 1. pii: S0085-2538(20)30969.
    PubMed     Abstract available

    April 2020
  81. VAN BOMMEL EJM, Lytvyn Y, Perkins BA, Soleymanlou N, et al
    Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.
    Kidney Int. 2020;97:631-635.

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.